HBM Holdings Limited

Informe acción SEHK:2142

Capitalización de mercado: HK$881.8m

HBM Holdings Dirección

Dirección controles de criterios 2/4

We currently do not have sufficient information about the CEO.

Información clave

Jingsong Wang

Chief Executive Officer (CEO)

US$1.6m

Compensación total

Porcentaje del salario del CEO55.8%
Permanencia del CEO8.3yrs
Participación del CEO8.4%
Permanencia media de la direcciónless than a year
Promedio de permanencia en la Junta Directiva4.3yrs

Actualizaciones recientes de la dirección

Recent updates

Investors Still Aren't Entirely Convinced By HBM Holdings Limited's (HKG:2142) Revenues Despite 30% Price Jump

Oct 02
Investors Still Aren't Entirely Convinced By HBM Holdings Limited's (HKG:2142) Revenues Despite 30% Price Jump

Not Many Are Piling Into HBM Holdings Limited (HKG:2142) Just Yet

Jul 18
Not Many Are Piling Into HBM Holdings Limited (HKG:2142) Just Yet

HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly

May 23
HBM Holdings (HKG:2142) Seems To Use Debt Quite Sensibly

Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

Apr 12
Take Care Before Jumping Onto HBM Holdings Limited (HKG:2142) Even Though It's 28% Cheaper

HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Jan 01
HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement

We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

Feb 08
We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate

HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

May 30
HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business

Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)

Apr 07
Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)

Here's What Analysts Are Forecasting For HBM Holdings Limited (HKG:2142) After Its Full-Year Results

Mar 31
Here's What Analysts Are Forecasting For HBM Holdings Limited (HKG:2142) After Its Full-Year Results

What Type Of Shareholders Own The Most Number of HBM Holdings Limited (HKG:2142) Shares?

Mar 10
What Type Of Shareholders Own The Most Number of HBM Holdings Limited (HKG:2142) Shares?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jingsong Wang en comparación con los beneficios de HBM Holdings?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2024n/an/a

US$21m

Mar 31 2024n/an/a

US$22m

Dec 31 2023US$2mUS$885k

US$23m

Sep 30 2023n/an/a

-US$19m

Jun 30 2023n/an/a

-US$61m

Mar 31 2023n/an/a

-US$99m

Dec 31 2022US$2mUS$781k

-US$137m

Sep 30 2022n/an/a

-US$143m

Jun 30 2022n/an/a

-US$149m

Mar 31 2022n/an/a

-US$144m

Dec 31 2021US$13mUS$13m

-US$138m

Sep 30 2021n/an/a

-US$224m

Jun 30 2021n/an/a

-US$310m

Mar 31 2021n/an/a

-US$303m

Dec 31 2020US$21mUS$654k

-US$296m

Compensación vs. Mercado: Jingsong's total compensation ($USD1.59M) is above average for companies of similar size in the Hong Kong market ($USD234.60K).

Compensación vs. Ingresos: Jingsong's compensation has been consistent with company performance over the past year.

CEO

Jingsong Wang (59 yo)

8.3yrs

Permanencia

US$1,585,000

Compensación

Dr. Jingsong Wang M.D., Ph D., serves as Chairman of Board of Directors of HBM Alpha Therapeutics, Inc. He has been Chief Executive Officer of HBM Holdings Limited and Harbour BioMed Shanghai Co., Ltd. sin...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Jingsong Wang
Founderno dataUS$1.59m8.4%
HK$ 74.1m
Yiping Rong
Chief Scientific Officer & Executive Director1.9yrsUS$547.00k0.028%
HK$ 244.8k
Youchen Chen
VP and Head of Investor Relations & Corporate Developmentless than a yearsin datossin datos
Bruce Zhang
VP & Head of Legal Affairsno datasin datossin datos
Peter Moesta
Member of Scientific Advisory Board & Chief CMC Advisorno datasin datossin datos
Xiaolu Tao
Chief Development Officerno datasin datossin datos
Steve Arkinstall
Chief Scientific Advisor1.4yrssin datossin datos
Ben Chih
Chief Scientific Officer of Neurosciences - Harbour BioMed USless than a yearsin datossin datos
Michael Lee
Senior VP & Head of Biometricsless than a yearsin datossin datos
Amy Jiang
VP, Chief of Staff & Head of Quality Departmentless than a yearsin datossin datos
Yuanqing Wei
VP & Head of Translational Developmentless than a yearsin datossin datos
Wing Yat Lui
Joint Company Secretaryno datasin datossin datos

0.3yrs

Permanencia media

48yo

Promedio de edad

Equipo directivo experimentado: 2142's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Jingsong Wang
Founder8.3yrsUS$1.59m8.4%
HK$ 74.1m
Yiping Rong
Chief Scientific Officer & Executive Director2.5yrsUS$547.00k0.028%
HK$ 244.8k
Peter Moesta
Member of Scientific Advisory Board & Chief CMC Advisorno datasin datossin datos
Robert Kamen
Independent Non-Executive Director & Member of Scientific Advisory Board7.9yrsUS$50.00k0.36%
HK$ 3.2m
Albert R. Collinson
Independent Non-Executive Director1.3yrsUS$21.00ksin datos
Alexander A. Zukiwski
Member of Scientific Advisory Board2.5yrssin datossin datos
Xiaoping Ye
Independent Non-Executive Director4yrsUS$50.00ksin datos
Jon Marc Wigginton
Member of Scientific Advisory Board4.4yrssin datossin datos
Robert Kramer
Member of Scientific Advisory Board7.9yrssin datossin datos
Frank Grosveld
Member of Scientific Advisory Board7.9yrssin datossin datos
Weiwei Chen
Senior Business Adviser & Non-Executive Director4yrsUS$50.00ksin datos
Zhigang Tian
Member of Scientific Advisory Board4.3yrssin datossin datos

4.3yrs

Permanencia media

61.5yo

Promedio de edad

Junta con experiencia: 2142's board of directors are considered experienced (4.3 years average tenure).